TI
ALLO icon

Tidal Investments’s Allogene Therapeutics ALLO Stock Holding History

Tidal Investments’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-219,072
Closed -$535K – 2602
2026
Q1 		$535K Buy
+219,072
New +$439K ﹤0.01% 1800
2025
Q2 		– Sell
-125,703
Closed -$184K – 1901
2025
Q1 		$184K Sell
125,703
-10,249
-8% -$19.3K ﹤0.01% 1699
2024
Q4 		$290K Sell
135,952
-6,795
-5% -$16.8K ﹤0.01% 1601
2024
Q3 		$400K Sell
142,747
-93,789
-40% -$250K ﹤0.01% 1485
2024
Q2 		$551K Buy
+236,536
New +$698K 0.01% 1247

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tidal Investments's ALLO Position: Q2 2026 in Review

Tidal Investments sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 219,072 shares — an estimated $535K sold.

Tidal Investments first reported a position in ALLO in Q2 2024 and held it in 5 quarters. The position peaked at $551K in Q2 2024. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Tidal Investments reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tidal Investments sold 219,072 Allogene Therapeutics shares in Q2 2026, an estimated $535K.
  • Tidal Investments first reported a position in Allogene Therapeutics in Q2 2024 and held it in 5 quarters.
  • Tidal Investments's Allogene Therapeutics position peaked at $551K in Q2 2024.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Tidal Investments's 13F filing for Q2 2026, filed 13 Aug 2026.